WO2017198224A1 - Pharmaceutical composition of remimazolam - Google Patents

Pharmaceutical composition of remimazolam Download PDF

Info

Publication number
WO2017198224A1
WO2017198224A1 PCT/CN2017/085141 CN2017085141W WO2017198224A1 WO 2017198224 A1 WO2017198224 A1 WO 2017198224A1 CN 2017085141 W CN2017085141 W CN 2017085141W WO 2017198224 A1 WO2017198224 A1 WO 2017198224A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxyethyl starch
remiazolam
composition
solution
composition according
Prior art date
Application number
PCT/CN2017/085141
Other languages
French (fr)
Chinese (zh)
Inventor
杨晓容
陈钟威
卢韵
Original Assignee
江苏恒瑞医药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏恒瑞医药股份有限公司 filed Critical 江苏恒瑞医药股份有限公司
Priority to CN201780004159.2A priority Critical patent/CN108289897B/en
Publication of WO2017198224A1 publication Critical patent/WO2017198224A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Definitions

  • the present invention is in the field of pharmaceutical preparations, and in particular relates to a composition comprising remimagazole and a pharmaceutically acceptable salt thereof.
  • Remiazolam is a sedative superior to the similar products currently in use, with rapid onset and failure, stable sedation, short recovery time, short half-life, inactive metabolites, predictable pharmacokinetics, and wide therapeutic window
  • the potential for interaction between drugs is low, and flumazenil can reverse the sedative effect and will not calm again. It was developed to obtain a new drug that combines the active activities of midazolam and propofol while discarding related defects. According to the results of the study, remiazolam is superior to these two products already on the market and is a breakthrough new chemical entity that is highly likely to become the new gold standard in the field of sedation/anaesthesia.
  • CN101501019A discloses benzenesulfonate and its polymorphs, and discloses a series of possible compositions thereof, but does not disclose how to obtain a stable composition; CN103221414A discloses remarazol The p-toluenesulfonate and its polymorph, but no composition thereof are disclosed.
  • CN103202815A discloses a lyophilized formulation of remamazepine containing mannitol or glycine, but the concentration of remiazolam in such a solution before or after lyophilization Lower, the relative proportion of excipients is higher, and a large amount of solution is required for clinical use, which is very inconvenient.
  • CN104968348A discloses a combination of a benzodiazepine compound and at least one hygroscopic excipient, in particular lactose and/or dextran, but the excipient lactose is an animal-derived excipient due to possible residual impurities therein. Protein, there is a certain safety risk when injected in large quantities.
  • Rimamazol is hydrolyzed in aqueous solution as well as in long-term storage to produce inactive impurities as shown in formula (II), so it is necessary to provide a stable composition of remiazolam.
  • It is an object of the present invention to provide a composition comprising remimagazole or a pharmaceutically acceptable salt thereof and hydroxyethyl starch.
  • the hydroxyethyl starch may be selected from any model, such as hydroxyethyl starch 200/0.5, hydroxyethyl starch 130/0.4, preferably hydroxyethyl starch 130/0.4.
  • composition of the present invention is allowed to stand at 50 ° C for 7 days to increase the amount of impurities present in the form of the compound of the formula (II) or its salt by no more than 0.15%; or to leave the compound of the formula (II) or its salt at 50 ° C for 14 days.
  • the amount of impurities present in the form does not increase by more than 0.3%, preferably 0.2%, more preferably not more than 0.2%.
  • the composition does not contain mannitol or gan Amino acid.
  • the ratio of remiazolam or a pharmaceutically acceptable salt thereof to hydroxyethyl starch is not particularly limited, and in a preferred embodiment of the present invention, remiazolam or a pharmaceutically acceptable thereof
  • the weight ratio of salt to hydroxyethyl starch is from 1:0.1 to 1000, preferably from 1:1 to 1:50, more preferably from 1:1 to 1:20, most preferably from 1:1 to 1:10.
  • the composition is a lyophilized formulation.
  • a monosaccharide may also be added to the compositions of the present invention.
  • the monosaccharide may be selected from the group consisting of glucose, fructose, galactose, mannose, galactose, glucosamine and the like.
  • the lyophilized preparation of the present invention is reconstituted with water to the volume before lyophilization, and is determined according to the method of the Chinese Pharmacopoeia 2010 edition two appendix VI H, the pH of the solution is 2-7, more preferably 2-5. Most preferably 2 to 4.
  • the lyophilized formulation of the present invention can be reconstituted using various aqueous diluents to provide solutions for injection, such as water for injection, physiological saline, aqueous 5% dextrose, and the like, which are widely known in the art.
  • the ratio of the hydroxyethyl starch to the monosaccharide is not particularly limited, and in a preferred embodiment of the present invention, the weight ratio of the hydroxyethyl starch to the monosaccharide is from 1:9 to 9:1, more preferably 1:5. 5:1, most preferably 1:3 to 3:1.
  • the concentration of remazolium (in terms of free base) in the solution obtained by lyophilization or reconstitution with an aqueous diluent is about 0.5 to 30 mg/ml, preferably 1 to 20 mg/ml. It is particularly preferably 2 to 15 mg/ml.
  • the pharmaceutically acceptable salt of remiazolam may be a benzenesulfonate, a p-toluenesulfonate, an isethionate or the like.
  • the solution for injection can be reconstituted to obtain a clear solution after slight shaking, and the reconstitution time is less than 3 min, more preferably less than 2 min, most preferably less than 1.5 min; long time after dissolution or dilution Stabilization does not precipitate drug crystals.
  • the present invention provides a method of inhibiting degradation of remimalam or a pharmaceutically acceptable salt thereof to a compound of formula (II) or a salt thereof, the method comprising adding a hydroxy group as described above Ethyl starch or hydroxyethyl starch and monosaccharide.
  • hydroxyethyl starch, monosaccharides, and combinations thereof are capable of inhibiting the degradation of remazolam or a pharmaceutically acceptable salt thereof to a compound of formula (II) or a salt thereof, thereby further solving The problem of stability; hydroxyethyl starch, monosaccharide and combinations thereof are much stronger than the known glycine, mannitol, lactose and other common excipients.
  • the present invention provides a method of preparing a composition comprising remiazolam and a pharmaceutically acceptable salt thereof, which is simple in operation, good in reproducibility, and easy to industrialize.
  • the method includes the following steps:
  • the method further comprises the step of lyophilizing the solution obtained in step 3).
  • the product needs to have good stability, and the composition provided by the present invention exhibits excellent stability after drying, and the reconstitution rate does not change after standing.
  • the pharmaceutical preparation of the present invention is usually obtained by the following steps:
  • the solution is lyophilized.
  • Two bottles of the product were reconstituted with 2.0 ml of water for injection, reconstituted with a 5 ml syringe and a suitable needle, and the time required for the solid to completely dissolve was recorded.
  • the lyophilized products of the respective examples were reconstituted rapidly, and the appearance, the reconstitution time, and the appearance of the solution after reconstitution did not change significantly during storage at a high temperature of 50 ° C, and the CNS7054 related substance grew slowly, showing excellent stability.
  • the prescription for further addition of monosaccharides showed better stability.
  • Example II lactose prescription (A01P310 prescription) published in CN104968348A and the example 6 glycine prescription of CN103202815A, and prepare a remazole lyophilized powder needle by freeze-drying a sample disclosed in the patent at a high temperature of 50 ° C.
  • the stability was investigated under the conditions, and the results are shown in Table 1. Further, the lactose and glycine prescription lyophilized product and the lyophilized product of Example 4, Example 7 and Example 10 were respectively reconstituted with water for injection, and the stability of the solution at room temperature was examined. The results were compared. The results are shown in Table 3.
  • Table 1 The results of Table 1, Table 2 and Table 3 show that the stability of the rimazolam composition lyophilized product of the present invention at high temperature and the stability of the solution after reconstitution are superior to the patent prescription, especially remarazol and A combination of hydroxyethyl starch and a monosaccharide.

Abstract

Provided is a pharmaceutical composition of remimazolam. In particular, provided is a pharmaceutical composition comprising remimazolam or a pharmaceutically acceptable salt thereof and a hydroxyethyl starch and/or a monosaccharide composition. The composition provided by the present invention has a short reconstitution time after remimazolam drying, and is convenient for clinical medication and has good stability.

Description

一种瑞马***的药物组合物Pharmaceutical composition of rimazolam 技术领域Technical field
本发明属于药物制剂领域，具体涉及包含瑞马***及其药学上可接受的盐的组合物。The present invention is in the field of pharmaceutical preparations, and in particular relates to a composition comprising remimagazole and a pharmaceutically acceptable salt thereof.
背景技术Background technique
瑞马***(Remimazolam)化学名：(4S)-8-溴-1-甲基-6-(2-吡啶基)-4H-咪唑[1，2-a][1，4]苯并二氮卓-4-丙酸甲酯，结构式如式(I)所示，该化合物由GSK公司设计，PAION公司开发，代号CNS7056，为一种超速效的镇静、***，作用于GABAA受体，经组织酯酶代谢，***成无活性的代谢产物CNS7054，结构式如式(II)所示。Remimazolam chemical name: (4S)-8-bromo-1-methyl-6-(2-pyridyl)-4H-imidazole [1,2-a][1,4]benzoic Methyl azide-4-propionate, the structural formula is as shown in formula (I). This compound was designed by GSK Company and developed by PAION Company, code CNS7056. It is an ultra-fast sedative and anesthetic agent acting on GABAA receptors. Metabolized by tissue esterase, it is cleaved into inactive metabolite CNS7054, and the structural formula is as shown in formula (II).
Figure PCTCN2017085141-appb-000001
Figure PCTCN2017085141-appb-000001
瑞马***是一种优于目前正在使用的同类产品的镇静剂，起效和失效迅速，镇静作用稳定，恢复时间短，半衰期短，代谢产物无活性，药代动力学可预测，治疗窗广，药物间相互作用的潜在性较低，氟马西尼可逆转镇静作用，不会再次镇静。其开发目的是为获得一种集合咪达***和异丙酚的积极活性，而摒弃相关缺陷的新型药物。根据研究结果，瑞马***优于这两种已上市销售的产品，是一种突破性的新化学实体，极有可能成为镇静/麻醉领域的新型金标准。 Remiazolam is a sedative superior to the similar products currently in use, with rapid onset and failure, stable sedation, short recovery time, short half-life, inactive metabolites, predictable pharmacokinetics, and wide therapeutic window The potential for interaction between drugs is low, and flumazenil can reverse the sedative effect and will not calm again. It was developed to obtain a new drug that combines the active activities of midazolam and propofol while discarding related defects. According to the results of the study, remiazolam is superior to these two products already on the market and is a breakthrough new chemical entity that is highly likely to become the new gold standard in the field of sedation/anaesthesia.
CN101501019A公开了瑞马***的苯磺酸盐和其多晶型，并公开了其一系列可能制成的组合物，但是没有公开如何获得一种稳定的组合物；CN103221414A公开了瑞马***的对甲苯磺酸盐和其多晶型，但没有公开其组合物。CN101501019A discloses benzenesulfonate and its polymorphs, and discloses a series of possible compositions thereof, but does not disclose how to obtain a stable composition; CN103221414A discloses remarazol The p-toluenesulfonate and its polymorph, but no composition thereof are disclosed.
目前瑞马***还未上市，CN103202815A公开了一种含有甘露醇或甘氨酸的瑞马***冻干制剂，但是此类制剂在冻干前溶液或重建后的溶液中，瑞马***的浓度较低，辅料相对比例较高，临床使用需要大量溶液，十分不便。Currently, remiazolam has not been marketed, and CN103202815A discloses a lyophilized formulation of remamazepine containing mannitol or glycine, but the concentration of remiazolam in such a solution before or after lyophilization Lower, the relative proportion of excipients is higher, and a large amount of solution is required for clinical use, which is very inconvenient.
CN104968348A中公布了苯二氮杂卓类化合物和至少一种吸湿性赋形剂，特别是乳糖和/或葡聚糖的组合物，但赋形剂乳糖为动物来源辅料，由于其中可能残留的杂蛋白，大量注射时存在一定的安全性风险。CN104968348A discloses a combination of a benzodiazepine compound and at least one hygroscopic excipient, in particular lactose and/or dextran, but the excipient lactose is an animal-derived excipient due to possible residual impurities therein. Protein, there is a certain safety risk when injected in large quantities.
瑞马***在水溶液中以及长期储存中会水解产生如式(II)所示的无活性的杂质，因此提供一种稳定的瑞马***的组合物非常有必要。Rimamazol is hydrolyzed in aqueous solution as well as in long-term storage to produce inactive impurities as shown in formula (II), so it is necessary to provide a stable composition of remiazolam.
发明内容Summary of the invention
本发明的目的是提供一种含瑞马***或其药学上可接受的盐与羟乙基淀粉的组合物。It is an object of the present invention to provide a composition comprising remimagazole or a pharmaceutically acceptable salt thereof and hydroxyethyl starch.
所述的羟乙基淀粉可以选自任意型号，例如羟乙基淀粉200/0.5、羟乙基淀粉130/0.4，优选羟乙基淀粉130/0.4。The hydroxyethyl starch may be selected from any model, such as hydroxyethyl starch 200/0.5, hydroxyethyl starch 130/0.4, preferably hydroxyethyl starch 130/0.4.
本发明的组合物在50℃条件下放置7天以式(II)化合物或其盐形式存在的杂质增长不超过0.15％；或在50℃条件下放置14天以式(II)化合物或其盐形式存在的杂质增长不超过0.3％，选0.2％，更优选不超过0.2％。The composition of the present invention is allowed to stand at 50 ° C for 7 days to increase the amount of impurities present in the form of the compound of the formula (II) or its salt by no more than 0.15%; or to leave the compound of the formula (II) or its salt at 50 ° C for 14 days. The amount of impurities present in the form does not increase by more than 0.3%, preferably 0.2%, more preferably not more than 0.2%.
Figure PCTCN2017085141-appb-000002
Figure PCTCN2017085141-appb-000002
在本发明优选的实施方案中，所述的组合物中不含有甘露醇或甘 氨酸。In a preferred embodiment of the invention, the composition does not contain mannitol or gan Amino acid.
本发明的组合物中，瑞马***或其药学上可接受的盐与羟乙基淀粉的比例没有特别限制，在本发明优选的实施方案中，瑞马***或其药学上可接受的盐与羟乙基淀粉的重量比为1∶0.1～1000，优选的1∶1～1∶50，更优选的为1∶1～1∶20，最优选1∶1～1∶10。In the composition of the present invention, the ratio of remiazolam or a pharmaceutically acceptable salt thereof to hydroxyethyl starch is not particularly limited, and in a preferred embodiment of the present invention, remiazolam or a pharmaceutically acceptable thereof The weight ratio of salt to hydroxyethyl starch is from 1:0.1 to 1000, preferably from 1:1 to 1:50, more preferably from 1:1 to 1:20, most preferably from 1:1 to 1:10.
在本发明优选的实施方案中，所述的组合物为冻干制剂。In a preferred embodiment of the invention, the composition is a lyophilized formulation.
在更为优选的实施方案中，本发明的组合物中还可以加入单糖。所述的单糖可以选自葡萄糖、果糖、半乳糖、甘露糖、氨基半乳糖、氨基葡萄糖等。In a more preferred embodiment, a monosaccharide may also be added to the compositions of the present invention. The monosaccharide may be selected from the group consisting of glucose, fructose, galactose, mannose, galactose, glucosamine and the like.
本发明的冻干制剂，用水重构至冻干前的体积，并根据中国药典2010年版二部附录VI H项下的方法测定，该溶液的pH为2～7，更优选的为2～5，最优选的为2～4。The lyophilized preparation of the present invention is reconstituted with water to the volume before lyophilization, and is determined according to the method of the Chinese Pharmacopoeia 2010 edition two appendix VI H, the pH of the solution is 2-7, more preferably 2-5. Most preferably 2 to 4.
本发明的冻干制剂可以使用各种水性稀释剂重构后得到用于注射的溶液，所述的水性稀释剂是本领域广泛公知的，例如注射用水、生理盐水、5％葡萄糖水溶液等。The lyophilized formulation of the present invention can be reconstituted using various aqueous diluents to provide solutions for injection, such as water for injection, physiological saline, aqueous 5% dextrose, and the like, which are widely known in the art.
羟乙基淀粉与单糖的比例没有特别的限制，在本发明优选的实施方案中，羟乙基淀粉与单糖的重量比例为1∶9～9∶1，更优选的为1∶5～5∶1，最优选的为1∶3～3∶1。The ratio of the hydroxyethyl starch to the monosaccharide is not particularly limited, and in a preferred embodiment of the present invention, the weight ratio of the hydroxyethyl starch to the monosaccharide is from 1:9 to 9:1, more preferably 1:5. 5:1, most preferably 1:3 to 3:1.
在本发明的组合物中，冻干前溶液或使用水性稀释剂复溶后得到的溶液中瑞马***(以游离碱计)浓度约为0.5～30mg/ml，优选1～20mg/ml，特别优选2～15mg/ml。In the composition of the present invention, the concentration of remazolium (in terms of free base) in the solution obtained by lyophilization or reconstitution with an aqueous diluent is about 0.5 to 30 mg/ml, preferably 1 to 20 mg/ml. It is particularly preferably 2 to 15 mg/ml.
本发明中，瑞马***的药学上可接受的盐可以是苯磺酸盐、对甲苯磺酸盐，羟乙磺酸盐等。In the present invention, the pharmaceutically acceptable salt of remiazolam may be a benzenesulfonate, a p-toluenesulfonate, an isethionate or the like.
本发明提供的组合物制剂经干燥后，加入注射用溶剂后轻微振摇即可重构得到澄清溶液，重构时间小于3min，更优选小于2min，最优选小于1.5min；溶解或稀释后长时间静置不会析出药物晶体。After the preparation of the composition provided by the invention is added, the solution for injection can be reconstituted to obtain a clear solution after slight shaking, and the reconstitution time is less than 3 min, more preferably less than 2 min, most preferably less than 1.5 min; long time after dissolution or dilution Stabilization does not precipitate drug crystals.
另一方面，本发明还提供了一种抑制瑞马***或其药学上可接的盐降解为式(II)所示化合物或其盐的方法，所述方法包括加入如前所述的羟乙基淀粉或加入羟乙基淀粉和单糖。 In another aspect, the present invention provides a method of inhibiting degradation of remimalam or a pharmaceutically acceptable salt thereof to a compound of formula (II) or a salt thereof, the method comprising adding a hydroxy group as described above Ethyl starch or hydroxyethyl starch and monosaccharide.
Figure PCTCN2017085141-appb-000003
Figure PCTCN2017085141-appb-000003
本发明意外地发现，羟乙基淀粉、单糖及其组合物均能够抑制瑞马***或其药学上可接的盐降解为式(II)所示化合物或其盐，从而进一步地解决了稳定性的问题；羟乙基淀粉、单糖及其组合为对该种降解产物的抑制作用大大地强于已知的甘氨酸、甘露醇、乳糖等常见辅料。The present inventors have unexpectedly discovered that hydroxyethyl starch, monosaccharides, and combinations thereof are capable of inhibiting the degradation of remazolam or a pharmaceutically acceptable salt thereof to a compound of formula (II) or a salt thereof, thereby further solving The problem of stability; hydroxyethyl starch, monosaccharide and combinations thereof are much stronger than the known glycine, mannitol, lactose and other common excipients.
再一方面本发明还提供了一种制备含瑞马***及其药学上可接受的盐的组合物的方法，该方法操作简单、重现性良好，易于产业化。所述方法包括如下步骤：In still another aspect, the present invention provides a method of preparing a composition comprising remiazolam and a pharmaceutically acceptable salt thereof, which is simple in operation, good in reproducibility, and easy to industrialize. The method includes the following steps:
1)将羟乙基淀粉及任选的其它辅料(如单糖)溶解于水性稀释剂中，调节pH值至2-4，1) Dissolving hydroxyethyl starch and optionally other excipients (such as monosaccharides) in an aqueous diluent to adjust the pH to 2-4.
2)加入瑞马***或其盐，调节pH值至2-4，2) Add remazolam or its salt to adjust the pH to 2-4,
3)加入水性稀释剂至最终体积。3) Add the aqueous diluent to the final volume.
优选所述方法还包括将步骤3)所得溶液冻干的步骤。Preferably, the method further comprises the step of lyophilizing the solution obtained in step 3).
为达到较低的储存成本，产品需具有良好的稳定性，本发明提供的组合物制剂干燥后表现出了优异的稳定性，且放置后复溶速率未发生变化。In order to achieve a lower storage cost, the product needs to have good stability, and the composition provided by the present invention exhibits excellent stability after drying, and the reconstitution rate does not change after standing.
具体实施方式detailed description
以下实施例是为了阐述发明，并不以任何方式限制本发明的范围。The following examples are intended to illustrate the invention and are not intended to limit the scope of the invention in any way.
实施例1至11Examples 1 to 11
本发明的药物制剂通常通过下面的步骤制得：The pharmaceutical preparation of the present invention is usually obtained by the following steps:
1.称取处方量的羟乙基淀粉130/0.4(含单糖在该步骤添加)，搅拌溶解在至少一种水性稀释剂中，水性稀释剂为处方量的80％左右，水温控制在0-30℃，测定溶液的pH值，根据需要，使 用pH调节剂对溶液pH值进行调整，pH控制在2-4。1. Weigh a prescribed amount of hydroxyethyl starch 130/0.4 (containing monosaccharide in this step), stir and dissolve in at least one aqueous diluent, the aqueous diluent is about 80% of the prescription amount, and the water temperature is controlled at 0. Measure the pH of the solution at -30 ° C, as needed The pH of the solution was adjusted with a pH adjuster and the pH was controlled at 2-4.
2.称取处方量的瑞马***，搅拌溶解在上述溶液中，完全溶解后测定溶液的pH值，根据需要，使用pH调节剂对溶液pH值进行调整，pH控制在2-4。2. Weigh the prescribed amount of remiazolam, stir and dissolve in the above solution, and completely dissolve the solution to determine the pH value of the solution. If necessary, adjust the pH of the solution with a pH adjuster, and control the pH to 2-4.
3.加入水性稀释剂至最终体积，将溶液继续搅拌至混合均匀。3. Add the aqueous diluent to the final volume and continue stirring the solution until it is well mixed.
4.将上述的溶液过滤除菌。4. Filter the above solution to remove bacteria.
5.将溶液进行冷冻干燥。5. The solution is lyophilized.
Figure PCTCN2017085141-appb-000004
Figure PCTCN2017085141-appb-000004
Figure PCTCN2017085141-appb-000005
Figure PCTCN2017085141-appb-000005
冷冻干燥：Freeze drying:
6ml瓶灌装2ml药液，半加塞后按如下程序冻干。Fill the 6ml bottle with 2ml of liquid medicine. After half-filling, freeze it as follows.
冻干程序：Freeze-drying procedure:
Figure PCTCN2017085141-appb-000006
Figure PCTCN2017085141-appb-000006
Figure PCTCN2017085141-appb-000007
Figure PCTCN2017085141-appb-000007
考察实施例1-11产品冻干后的冻干品外观、重构时间、重构后溶液外观、水分、有关物质，并分别在高温50℃条件下进行稳定性考察。The appearance of the lyophilized product after lyophilization of the products of Example 1-11, the reconstitution time, the appearance of the solution after reconstitution, moisture, and related substances were examined, and the stability was investigated at a high temperature of 50 ° C, respectively.
检验方法：Testing method:
1、重构时间1, reconstruction time
用2.0ml注射用水，使用5ml注射器和合适的针头复溶重构2瓶制品，记录固体完全溶解所需时间。Two bottles of the product were reconstituted with 2.0 ml of water for injection, reconstituted with a 5 ml syringe and a suitable needle, and the time required for the solid to completely dissolve was recorded.
2、复溶后外观2, the appearance after reconstitution
记录重构后溶液的外观。The appearance of the solution after reconstitution was recorded.
3、水分3, moisture
通过卡尔.费歇尔(Karl Fischer)滴定测定水分，通过消耗滴定液的体积计算出水分含量，结果由仪器显示。Moisture was measured by Karl Fischer titration, and the moisture content was calculated by consuming the volume of the titration solution, and the results were shown by the instrument.
4、有关物质4. Related substances
采用HPLC方法检测，产品最主要的降解杂质为CNS7054(即式(II)化合物)。The most important degradation impurity of the product was determined by HPLC method, CNS7054 (ie, the compound of formula (II)).
结果见表1与表2。The results are shown in Tables 1 and 2.
各实施例的冻干制品重构迅速，在高温50℃储存过程中外观、重构时间、重构后溶液外观未发生明显变化，CNS7054有关物质增长缓慢，表现出优良的稳定性。进一步添加单糖的处方表现出更佳的稳定性。The lyophilized products of the respective examples were reconstituted rapidly, and the appearance, the reconstitution time, and the appearance of the solution after reconstitution did not change significantly during storage at a high temperature of 50 ° C, and the CNS7054 related substance grew slowly, showing excellent stability. The prescription for further addition of monosaccharides showed better stability.
实施例12Example 12
参照CN104968348A专利中公布的实施例II乳糖处方(A01P310处方)及CN103202815A的实施例6甘氨酸处方，并用专利中公布的对一个工艺进行冻干样品制备瑞马***冻干粉针，在高温50℃条件下进行稳定性考察，结果见表1。此外，将乳糖与甘氨酸处方冻干品与实施例4、实施例7和实施例10冻干品分别用注射用水重构后，进行室温溶液稳定性考察，结果进行对比，结果见表3。 Refer to the Example II lactose prescription (A01P310 prescription) published in CN104968348A and the example 6 glycine prescription of CN103202815A, and prepare a remazole lyophilized powder needle by freeze-drying a sample disclosed in the patent at a high temperature of 50 ° C. The stability was investigated under the conditions, and the results are shown in Table 1. Further, the lactose and glycine prescription lyophilized product and the lyophilized product of Example 4, Example 7 and Example 10 were respectively reconstituted with water for injection, and the stability of the solution at room temperature was examined. The results were compared. The results are shown in Table 3.
表1、表2和表3结果表明，本发明中的瑞马***组合物冻干品在高温下稳定性以及重构后的溶液稳定性均优于专利处方，尤其是瑞马***与羟乙基淀粉和单糖的组合物。 The results of Table 1, Table 2 and Table 3 show that the stability of the rimazolam composition lyophilized product of the present invention at high temperature and the stability of the solution after reconstitution are superior to the patent prescription, especially remarazol and A combination of hydroxyethyl starch and a monosaccharide.
Figure PCTCN2017085141-appb-000008
Figure PCTCN2017085141-appb-000008
Figure PCTCN2017085141-appb-000009
Figure PCTCN2017085141-appb-000009
表3重构后溶液稳定性结果Table 3 solution stability results after reconstitution
Figure PCTCN2017085141-appb-000010
Figure PCTCN2017085141-appb-000010

Claims (12)

  1. 一种药物组合物，含有瑞马***或其药学上可接受的盐以及羟乙基淀粉。A pharmaceutical composition comprising remiazolam or a pharmaceutically acceptable salt thereof and hydroxyethyl starch.
  2. 根据权利要求1所述的组合物，其中所述的羟乙基淀粉选自羟乙基淀粉200/0.5和羟乙基淀粉130/0.4中的一种或两种。The composition of claim 1 wherein said hydroxyethyl starch is selected from one or both of hydroxyethyl starch 200/0.5 and hydroxyethyl starch 130/0.4.
  3. 根据权利要求1所述的组合物，其中所述的瑞马***或其药学上可接受的盐与羟乙基淀粉的重量比为1：0.1～1000，优选的为1:1～1:50，更优选的为1:1～1:20，最优选1:1～1:10。The composition according to claim 1, wherein the weight ratio of said remiazolam or a pharmaceutically acceptable salt thereof to hydroxyethyl starch is from 1:0.1 to 1000, preferably from 1:1 to 1: 50, more preferably 1:1 to 1:20, most preferably 1:1 to 1:10.
  4. 根据权利要求1所述的组合物，还含有单糖，优选所述单糖选自葡萄糖、果糖、半乳糖、甘露糖、氨基半乳糖、氨基葡萄糖中的一种或几种。The composition according to claim 1, further comprising a monosaccharide, preferably the monosaccharide is one or more selected from the group consisting of glucose, fructose, galactose, mannose, galactose, and glucosamine.
  5. 根据权利要求4所述的组合物，其中所述的羟乙基淀粉与单糖的重量比例为1:9～9:1，更优选的为1:5～5:1，最优选的为1:3～3:1。The composition according to claim 4, wherein the weight ratio of said hydroxyethyl starch to monosaccharide is from 1:9 to 9:1, more preferably from 1:5 to 5:1, most preferably 1 : 3 to 3:1.
  6. 根据权利要求1所述的组合物，所述组合物为溶液形式，其中瑞马***或其盐的浓度以瑞马***碱计为0.5～30mg/ml，优选1～20mg/ml，更优选2～15mg/ml。The composition according to claim 1, wherein the composition is in the form of a solution, wherein the concentration of remiazolam or a salt thereof is 0.5 to 30 mg/ml, preferably 1 to 20 mg/ml, based on the remiazolam base, more It is preferably 2 to 15 mg/ml.
  7. 根据权利要求1至6任一项所述的组合物，其中所述的瑞马***的盐选自苯磺酸盐、对甲苯磺酸盐和羟乙基磺酸盐中的一种。The composition according to any one of claims 1 to 6, wherein the salt of remiazolam is selected from the group consisting of benzenesulfonate, p-toluenesulfonate and isethionate.
  8. 根据权利要求1至5任一项所述的组合物，其中所述组合物为冻干制剂。The composition according to any one of claims 1 to 5, wherein the composition is a lyophilized preparation.
  9. 根据权利要求8所述的组合物，其中所述冻干制剂的冻干前溶液或复溶后溶液中瑞马***或其盐的浓度以瑞马***碱计为0.5～30mg/ml，优选1～20mg/ml，更优选2～15mg/ml。 The composition according to claim 8, wherein the concentration of remiazolam or a salt thereof in the pre-lyophilized solution or the reconstituted solution of the lyophilized preparation is 0.5 to 30 mg/ml based on the remiazolam base. It is preferably 1 to 20 mg/ml, more preferably 2 to 15 mg/ml.
  10. 权利要求1至5任一项所述的组合物的制备方法，包括如下步骤：A method of preparing a composition according to any one of claims 1 to 5, comprising the steps of:
    1)将羟乙基淀粉或羟乙基淀粉和单糖溶解于水性稀释剂中，1) dissolving hydroxyethyl starch or hydroxyethyl starch and monosaccharide in an aqueous diluent,
    2)加入瑞马***或其盐，2) adding remiazolam or its salt,
    3)加入水性稀释剂至最终体积。3) Add the aqueous diluent to the final volume.
  11. 根据权利要求10所述的制备方法，还包括将步骤3)所得溶液冻干的步骤。The preparation method according to claim 10, further comprising the step of lyophilizing the solution obtained in the step 3).
  12. 根据权利要求10所述的制备方法，其中还包括将步骤1)、2)、3)中任意一步或多步中所得溶液的pH调节至2-4的步骤。 The production method according to claim 10, which further comprises the step of adjusting the pH of the solution obtained in any one or more of steps 1), 2), 3) to 2-4.
PCT/CN2017/085141 2016-05-20 2017-05-19 Pharmaceutical composition of remimazolam WO2017198224A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201780004159.2A CN108289897B (en) 2016-05-20 2017-05-19 Pharmaceutical composition of remazolam

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610340803 2016-05-20
CN201610340803.0 2016-05-20

Publications (1)

Publication Number Publication Date
WO2017198224A1 true WO2017198224A1 (en) 2017-11-23

Family

ID=60324790

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/085141 WO2017198224A1 (en) 2016-05-20 2017-05-19 Pharmaceutical composition of remimazolam

Country Status (2)

Country Link
CN (1) CN108289897B (en)
WO (1) WO2017198224A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111514103A (en) * 2020-05-18 2020-08-11 安徽省逸欣铭医药科技有限公司 Stable remazolam injection composition and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104546675A (en) * 2014-12-25 2015-04-29 海南卫康制药(潜山)有限公司 Estazolam composition freeze-dried tablet and preparation method thereof
CN104968348A (en) * 2012-05-22 2015-10-07 Paion英国有限公司 Compositions comprising short-acting benzodiazepines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104968348A (en) * 2012-05-22 2015-10-07 Paion英国有限公司 Compositions comprising short-acting benzodiazepines
CN104546675A (en) * 2014-12-25 2015-04-29 海南卫康制药(潜山)有限公司 Estazolam composition freeze-dried tablet and preparation method thereof

Also Published As

Publication number Publication date
CN108289897B (en) 2020-07-28
CN108289897A (en) 2018-07-17

Similar Documents

Publication Publication Date Title
EP2822591B1 (en) Pharmaceutical formulations of tnf-alpha antibodies
JP6313286B2 (en) Composition comprising a short-acting benzodiazepine
JP5406197B2 (en) Co-solvent compositions and methods for improving delivery of dantrolene therapeutics
US20210077564A1 (en) Manufacture of degarelix
JP7409772B2 (en) Aqueous composition containing dantrolene
JP6869941B2 (en) A method for producing a lyophilized pharmaceutical composition having a certain content of mitomycin C.
JP2020509070A (en) Pharmaceutical composition containing selexipag
JP6942182B2 (en) Parenteral drug formulation containing calglumic acid
JP2018531268A6 (en) Aqueous composition containing dantrolene
AU2017422167A1 (en) Preparation of Pulsatilla saponin B4 for injection
WO2005004874A1 (en) Stable tetrodotoxin freeze drying medicinal preparation
CN104721155A (en) Temozolomide lyophilized powder preparation and preparation method thereof
CN102481288B (en) Pharmaceutical composition of temozolomide comprising amino acid stabilizer and preparation method thereof
BR112013005763B1 (en) 5A-ANDROSTANE-3SS, 5, 6SS-TRIOL INJECTION AND INJECTION PREPARATION METHOD
TWI696469B (en) Formulation
JP7271517B2 (en) Parenteral preparations containing Siponimod
CN104800172B (en) Injection Carbazochrome Sodium Sulfonate powder-injection and preparation method
WO2017198224A1 (en) Pharmaceutical composition of remimazolam
TWI650133B (en) Medicinal composition containing micafungin or a salt thereof
JP2023536509A (en) Pharmaceutical composition of aquaporin inhibitor and method for producing the same
CN103315970B (en) Ranitidine hydrochloride powder injection for injection
WO2016197738A1 (en) Pharmaceutical composition
WO2009043226A1 (en) A stable liquid composition comprising taxan derivatives and its preparation method.
JP3421330B2 (en) Vidarabine dry preparation for injection
CN106176626B (en) L-alanine- (14-oridonin) ester parenteral pharmaceutical composition

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17798787

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17798787

Country of ref document: EP

Kind code of ref document: A1